ROR1 targeting chimeric antigen receptors (CAR) T cell therapy has shown antitumour efficacy in vivo [38] and a humanised monoclonal antibody developed against ROR1 Fz and Ig-like domain, cirmtuzumab has demonstrated safety and efficacy in several Phase I/II clinical trials for patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) (NCT03088878) and Her2-negative breast cancer (NCT02776917) [30, 31]. Here, ERBB2 is linked to mantle cell lymphoma.